How does Chlordehydromethyltestosterone fit into a modern structured anabolic cycle?

Modern cycle architects position Turinabol as a versatile phase compound — placed at the start, middle, or closing weeks of a stack depending on the protocol's goals. Its clearance profile, confirmed by IRMS metabolite detection data, allows practitioners to plan its exit from the protocol with precision. Paired with a testosterone base, Turinabol's SHBG suppression raises free-androgen availability throughout the phase it occupies.

At what point in a cycle should you introduce Turinabol 10mg tablets?

Entry timing depends on the cycle architecture. Modern protocols commonly introduce Turinabol in week one alongside a long-ester injectable, using the oral compound to generate anabolic activity during the period before the injectable reaches steady-state plasma concentration. Alternatively, some practitioners deploy it mid-cycle as a bridge, or in the final four to six weeks as a finishing compound during a caloric deficit phase.

How long does a modern Turinabol cycle typically run within a broader stack?

Contemporary protocol design generally places Turinabol use within a four-to-eight-week window inside a longer injectable stack. Liver enzyme monitoring via ALT and AST assay panels at weeks two and four guides duration decisions. Staying within eight weeks limits cumulative hepatic exposure while still delivering a complete dose-arc — whether a flat-dose bridge or a pyramid structure — within the 100-tablet pack.

Why is the 10mg per tablet format specifically useful for cycle dose management?

The 10 mg indivisible tablet unit is the smallest per-tablet dose available in the oral Turinabol category, making it the most granular tool for cycle phase adjustments. Ascending from 20 mg to 30 mg, or descending from 30 mg to 10 mg during a taper, requires only single-tablet step changes — no splitting, no dose variability introduced by uneven tablet fragments. Every phase transition in a modern periodised cycle executes cleanly.

Does the 100-tablet pack cover a complete modern cycle without reordering?

Yes, for the most common modern cycle structures. A five-week ascending-and-descending pyramid peaking at 30 mg daily uses approximately 105 tablets, making a single pack nearly sufficient; a six-week flat-dose run at 20 mg daily consumes 84 tablets, leaving a comfortable buffer. Protocol structures running eight weeks at 20 mg daily use exactly 112 tablets, requiring two packs — or one pack for a single-phase block within a longer injectable stack. (2) angle_used

Back in Stock

Military Pharma

Turinabol 10mg/tab 100 Tabletten by Military Pharma

Name: Turinabol 10mg/tab 100 Tablets by Military Pharma
Brand: Military Pharma
SKU: ORA-CHLOR-MIL-011
Price: 55.00 EUR
Availability: InStock

Military Pharma Turinabol delivers Chlordehydromethyltestosterone at 10 mg per tablet across a 100-tablet pack, structured to integrate at any phase of a periodised anabolic protocol — whether that is the opening block, a mid-cycle bridge, or the controlled step-down toward cycle end. Each 10 mg tablet represents one indivisible unit, enabling clean phase-to-phase dose adjustments without the gravimetric variability that tablet splitting introduces. Batch-release documentation for every production run encompasses HPLC content verification, GMP-compliant tableting parameters, and LAL endotoxin screening — three independent quality checkpoints applied before any pack enters distribution.

€55.00Free shipping on orders over €300

In stock

Ships within 48 h Lab-tested batch

Chlordehydromethyltestosterone at 10 mg per tablet enables single-step phase transitions across every stage of a modern periodised cycle.
HPLC-verified per-tablet content uniformity ensures ALT/AST monitoring data reflects actual compound exposure, not API variation.
SHBG suppression raises the free testosterone fraction when paired with an injectable base, amplifying the stack's anabolic output.
The 100-tablet pack covers the most common four-to-eight-week cycle structures within a single purchase.
GMP-compliant tableting parameters and LAL endotoxin screening support consistent tablet integrity from first dose to final taper tablet.
No aromatisation means estrogen-related side effects are not a primary management concern within the cycle phase.
Defined IRMS-confirmed metabolite clearance data allows practitioners to plan the compound's exit from a protocol with accuracy.

Phase	dosage	Note
Cycle Opening (Weeks 1–2)	20 mg/day (2 × 10 mg tablets)	Establishes baseline Chlordehydromethyltestosterone plasma levels alongside a long-ester injectable; tolerance assessment period.
Main Phase (Weeks 3–6)	30 mg/day (3 × 10 mg tablets)	Core anabolic phase; ALT/AST assay panel at week 4 guides continuation decision.
Closing Taper (Week 7)	20 mg/day (2 × 10 mg tablets)	Step-down reduces daily hepatic exposure while the injectable base continues at full dose.
Final Taper (Week 8)	10 mg/day (1 × 10 mg tablet)	Controlled final-week reduction before oral compound cessation; injectable stack continues independently.
Post-Cycle (Weeks 9 onward)	0 mg Turinabol	SERM-based PCT initiated as injectable compound clears; HPG axis recovery monitored via LH/FSH assay.

Key takeaways

Position Turinabol at any cycle phase — opener, mid-cycle bridge, or taper.
Adjust daily dose in clean 10mg tablet steps without splitting.
Monitor ALT and AST at weeks two and four during any cycle block.
Pair with a testosterone base to leverage SHBG suppression effectively.
Verify HPLC batch documentation to confirm per-tablet API uniformity before use.

Chlordehydromethyltestosterone as a Structured Cycle Component

Military Pharma Turinabol is a 10 mg per tablet oral anabolic steroid containing Chlordehydromethyltestosterone, formulated specifically to occupy a defined role within modern periodised cycle architecture rather than serving as a standalone compound. Modern cycle design treats Turinabol as a versatile block that can be positioned at multiple points in a protocol: an introductory phase compound, a mid-cycle bridge, or a closing agent during the final weeks of a stack. Compared to older protocol frameworks that assigned fixed six-to-eight-week flat-dose runs, contemporary practitioners structure Turinabol use around the compound's pharmacological characteristics — including its clearance window, confirmed by IRMS-validated metabolite detection data — to maximise output relative to exposure duration.

How Modern Cycle Planning Uses the 10 mg Tablet Format

The 10 mg per tablet format directly enables the dose architecture that modern cycle planning requires. A periodised protocol may begin Turinabol at 20 mg daily in week one, escalate to 30 mg by week three once tolerance is established, then taper back to 20 mg and finally 10 mg in the closing weeks as the injectable base continues. Each phase adjustment is executed in clean single-tablet steps — no tablet splitting, no gravimetric dose error. The 100-tablet pack supports a range of modern protocol structures: a five-week ascending-and-descending dose pyramid, a six-week flat mid-cycle bridge alongside a long-ester testosterone base, or a four-week opener followed by a controlled two-week step-down.

Cycle Length, Compound Pairing, and Monitoring Within Modern Protocols

Modern practitioners place Turinabol cycle length within four to eight weeks of the total stack, calibrating duration against liver enzyme monitoring data collected at weeks two and four using ALT/AST assay panels. Military Pharma's HPLC-verified per-tablet content uniformity — within documented tolerance of declared strength — means ALT/AST readings reflect actual compound exposure rather than a variable API load introduced by content inconsistency. Chlordehydromethyltestosterone suppresses SHBG, which raises the free fraction of co-administered testosterone; this interaction is quantified via equilibrium dialysis methodology and is a core reason modern cycle architects pair Turinabol with a testosterone base rather than running it solo. The 100-tablet pack provides the complete supply required for a well-structured modern cycle — approximately five to six weeks at 30 mg daily, or eight weeks at 20 mg — with no mid-cycle reorder.

Manufacturing Quality Supporting Protocol Reliability

GMP-compliant manufacturing, HPLC API verification, and LAL endotoxin screening collectively ensure that every tablet in the Military Pharma Turinabol pack delivers the declared 10 mg dose. Protocol reliability in modern cycle design depends on content consistency across all tablets — from the first dose of the opening phase to the final taper tablet consumed in week eight.

Usage

Define your cycle architecture before starting — determine whether Turinabol will serve as an opener, mid-cycle bridge, or closing compound within the broader stack, and set total oral phase duration at four to eight weeks.
Begin at 20 mg daily (two tablets) in week one; split across morning and early afternoon administrations to maintain steady intra-day plasma levels without concentrating the full dose in a single window.
Escalate to 30 mg daily (three tablets) from week three onward if week-two tolerance is confirmed and no significant ALT elevation is observed; adjust tablet timing to three evenly spaced doses if splitting across three administrations.
Administer tablets with a moderate-fat meal to extend the absorption phase and reduce peak-to-trough plasma fluctuation compared to fasted intake.
Run a full ALT/AST liver enzyme panel at week two and again at week four; if ALT exceeds 2.5× the upper limit of normal, reduce daily dose by one tablet (10 mg) and reassess within seven days.
Execute the closing taper in clean single-tablet step-downs — from 30 mg to 20 mg in week seven, then to 10 mg in week eight — before discontinuing the oral compound entirely and initiating SERM-based PCT once the injectable base has cleared.

Warnings

contraindications: Chlordehydromethyltestosterone is contraindicated in individuals with pre-existing hepatic impairment, carcinoma of the prostate or breast, hypercalcaemia, or known hypersensitivity to 17α-alkylated androgens. Not for use in individuals under 18 years of age or during pregnancy.

side_effects: 17α-alkylation confers hepatotoxic potential; elevated ALT and AST are the primary clinical markers to monitor. Endogenous testosterone suppression occurs via HPG axis inhibition proportional to dose and duration. Mild androgenic effects including acne and accelerated scalp hair loss may occur in genetically predisposed individuals. Haematocrit elevation and lipid profile shifts — specifically HDL reduction — have been documented with oral androgen use.

monitoring: Obtain a baseline blood panel covering liver enzymes (ALT, AST), lipid profile (HDL, LDL, total cholesterol), haematocrit, and LH/FSH before commencing the cycle. Repeat liver and lipid panels at week two and week four of any Turinabol-containing phase. Discontinue oral compound if ALT exceeds 3× upper limit of normal at any monitoring point.

pct: SERM-based post-cycle therapy — typically Tamoxifen or Clomiphene — should be initiated once Chlordehydromethyltestosterone has cleared (approximately four to five days post-final-dose based on five-half-life washout) and the injectable base compound has reached near-complete plasma clearance. LH and FSH recovery should be confirmed by immunoassay before considering PCT completion.

Frequently asked questions

How does Chlordehydromethyltestosterone fit into a modern structured anabolic cycle?: Modern cycle architects position Turinabol as a versatile phase compound — placed at the start, middle, or closing weeks of a stack depending on the protocol's goals. Its clearance profile, confirmed by IRMS metabolite detection data, allows practitioners to plan its exit from the protocol with precision. Paired with a testosterone base, Turinabol's SHBG suppression raises free-androgen availability throughout the phase it occupies.
At what point in a cycle should you introduce Turinabol 10mg tablets?: Entry timing depends on the cycle architecture. Modern protocols commonly introduce Turinabol in week one alongside a long-ester injectable, using the oral compound to generate anabolic activity during the period before the injectable reaches steady-state plasma concentration. Alternatively, some practitioners deploy it mid-cycle as a bridge, or in the final four to six weeks as a finishing compound during a caloric deficit phase.
How long does a modern Turinabol cycle typically run within a broader stack?: Contemporary protocol design generally places Turinabol use within a four-to-eight-week window inside a longer injectable stack. Liver enzyme monitoring via ALT and AST assay panels at weeks two and four guides duration decisions. Staying within eight weeks limits cumulative hepatic exposure while still delivering a complete dose-arc — whether a flat-dose bridge or a pyramid structure — within the 100-tablet pack.
Why is the 10mg per tablet format specifically useful for cycle dose management?: The 10 mg indivisible tablet unit is the smallest per-tablet dose available in the oral Turinabol category, making it the most granular tool for cycle phase adjustments. Ascending from 20 mg to 30 mg, or descending from 30 mg to 10 mg during a taper, requires only single-tablet step changes — no splitting, no dose variability introduced by uneven tablet fragments. Every phase transition in a modern periodised cycle executes cleanly.
Does the 100-tablet pack cover a complete modern cycle without reordering?: Yes, for the most common modern cycle structures. A five-week ascending-and-descending pyramid peaking at 30 mg daily uses approximately 105 tablets, making a single pack nearly sufficient; a six-week flat-dose run at 20 mg daily consumes 84 tablets, leaving a comfortable buffer. Protocol structures running eight weeks at 20 mg daily use exactly 112 tablets, requiring two packs — or one pack for a single-phase block within a longer injectable stack. (2) angle_used

Manufacturer

Military Pharma's pricing policy for oral anabolic tablets — the commercial dimension most directly relevant to cycle planners budgeting across a multi-compound stack — is built around a cost-per-dose model rather than a premium-brand positioning strategy. The Turinabol 10 mg per tablet format at 100 tablets per pack delivers a cost-per-tablet figure that sits below the segment average for HPLC-verified oral anabolics, a positioning decision that Military Pharma sustains by controlling tableting costs at the manufacturing stage rather than absorbing margin loss at the distribution level. For athletes running a full eight-week cycle incorporating an injectable testosterone base, a PCT SERM, and a supporting oral compound, the oral Turinabol line item represents a minor share of total cycle expenditure — a result of Military Pharma's deliberate decision to price volume-format oral products accessibly without reducing the analytical quality-control requirements that govern batch release.

Product details

Brand	Military Pharma
Active ingredient	chlordehydromethyltestosterone
Also known as	Turinabol, T-Bol, Oral Turinabol, Military Pharma Turinabol
Strength	10 mg
Form	Tabletten
Pack size	100 pieces
Item number	ORA-CHLOR-MIL-011

Reviews

No reviews yet. Be the first to review this product.

Write a review

Reviews are written by users of this shop and are checked editorially before publication. Unless labelled “Verified purchase”, we do not verify that the review is based on an actual purchase.

Similar products

Apto-Turinabol 10mg/tab 50 Tablets by Beligas Pharmaceuticals

Lab Tested

Apto-Turinabol 10mg/tab 50 Tabletten by Beligas Pharmaceuticals

Apto-Turinabol is an oral anabolic agent delivering Chlorodehydromethyltestosterone at 10 mg per tablet — a DHT-lineage compound whose structural 4-chloro substitution selectively modulates androgen receptor binding while eliminating aromatase conversion. Each tablet occupies the lowest effective concentration tier in Beligas Pharmaceuticals' oral steroid range, making receptor-level dose titration straightforward for both introductory and precision protocols. Batch release is governed by HPLC-confirmed content verification and LAL endotoxin screening of all raw material inputs; GMP manufacturing discipline underpins every production step.

€37.00

Turanabol 20mg/tab 100 Tablets by Dragon-Pharma

HPLC Verified

Turanabol 20mg/tab 100 Tabletten by Dragon-Pharma

Dragon-Pharma Turanabol delivers Chlorodehydromethyltestosterone at 20 mg per tablet — a 17α-alkylated oral anabolic whose pharmacokinetic profile is defined by a plasma half-life of approximately 16 hours, enabling once- or twice-daily dosing to sustain steady anabolic blood levels throughout an entire training cycle. Each 100-tablet jar is produced within a GMP-certified facility; HPLC quantification against a certified reference standard is applied to every batch before a release certificate is issued.

€75.00

Turinadyn 10mg/tab 100 Tablets by Driada Medical

Pharma Grade

Turinadyn 10mg/tab 100 Tabletten by Driada Medical

Turinadyn delivers Chlordehydromethyltestosterone at 10 mg per tablet in a 100-tablet format, distinguished among oral anabolic compounds by the measurable bioavailability advantage that arises precisely because it bypasses the intramuscular injection route — forgoing parenteral delivery in exchange for a clinically relevant oral absorption pathway shaped by hepatic first-pass processing. Unlike hypothetical injectable formulations of the same molecule, the oral tablet form achieves systemic exposure through gastrointestinal uptake, with 17α-alkylation preserving enough active compound after liver transit to produce consistent plasma levels. Quality assurance: every Turinadyn batch is released only after HPLC content verification of the Chlordehydromethyltestosterone API and LAL endotoxin screening under GMP Standard conditions at Driada Medical's facility.

€55.00

Turinabol 10mg/tab 100 Tablets by Elbrus Pharmaceuticals

Purity Tested

Turinabol 10mg/tab 100 Tabletten by Elbrus Pharmaceuticals

Elbrus Pharmaceuticals Turinabol delivers Chlordehydromethyltestosterone at 10 mg per tablet across 100 tablets, functioning as a non-aromatising oral anabolic agent that research associates with measurable shifts in nutrient partitioning and peripheral glucose metabolism. Each tablet supports lean tissue accretion while influencing insulin sensitivity in a dose-dependent manner — a metabolic profile that distinguishes it within the oral androgen class. Quality assurance is embedded at every stage: HPLC release testing confirms declared potency per batch, LAL endotoxin screening covers each production run, and GMP-certified API sourcing underpins the entire manufacturing chain.

€60.00

Stack it with

Pairs well with these products.

High Concentration

Quant-Equipoise 300mg/ml 10ml Vial by Beligas Pharmaceuticals

Quant-Equipoise by Beligas Pharmaceuticals is a high-concentration injectable anabolic agent delivering 300 mg of Boldenone Undecylenate per millilitre in a 10 ml multi-dose vial, purpose-built for integration into contemporary cycle structures where weekly injection frequency and volume efficiency are primary design criteria. The compound's extended ester profile supports low-frequency administration windows that align with modern 7-day dosing blocks used in both bulking and body-recomposition protocols. Quality assurance is enforced at two independent checkpoints: HPLC-verified potency assay and LAL bacterial endotoxin testing — both completed before batch release under Beligas's GMP-certified production framework.

€47.00

Bolden-250 250mg/ml 10x1ml Ampoules by BM Pharmaceuticals

Long-Acting Formula

Bolden-250 250mg/ml 10x1ml Ampullen by BM Pharmaceuticals

Bolden-250 is a veterinary-derived anabolic compound reformulated for human performance use, delivering Boldenone Undecylenate at 250 mg/ml via single-dose ampoule — distinguished by its exceptionally prolonged plasma half-life of approximately 14 days, which governs the entire pharmacokinetic profile and dictates injection scheduling. The undecylenate ester attached to the boldenone base controls the rate of hydrolysis in muscle tissue, producing a slow, steady release curve that maintains stable serum concentrations over extended periods. Quality verification is built into every step of production: HPLC-confirmed potency, LAL endotoxin screening, and GMP-compliant fill-finish at BM Pharmaceuticals' certified facility.

€48.00

Brand Quality

EquiTrex 350mg/ml 10ml Vial by Concentrex Labs

EquiTrex is a high-concentration boldenone undecylenate injectable — 350 mg per millilitre in a 10 ml vial — engineered to serve distinct roles across both the blast and cruise phases of a structured performance cycle. Its extended ester release supports stable androgen exposure during lower-dose cruise periods while delivering meaningful anabolic output when dose is escalated during a blast. Quality assurance at Concentrex Labs is built on HPLC potency verification and LAL endotoxin screening; every released batch carries documented evidence of sterility and concentration accuracy.

€52.00

Pro Choice

EQ 300 300mg/ml 10ml Vial by Dragon-Pharma

Dragon-Pharma EQ 300 delivers Boldenone Undecylenate at 300 mg/ml in a 10 ml multi-dose vial, formulated specifically for older athletes and TRT-adjacent users who require a mild yet effective anabolic agent to complement age-related hormonal management strategies. Its gradual plasma release profile makes it particularly suited to the steadier hormonal environment that men over 40 typically need to maintain lean mass, bone density support, and nitrogen retention without the volatility of shorter-ester androgens. Quality is assured at the batch level: every vial passes HPLC content verification and LAL endotoxin screening before release under full GMP compliance.

€44.00